Our Services
Medical Information
Helpful Resources
Published on: 9/26/2026
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a synthetic, chemically altered version of the natural growth factor IGF-1, engineered to stay active in the body far longer than the hormone it mimics, which is why it is sold on the research chemical and bodybuilding black market rather than as an approved medicine. It is considered risky because that extended activity can drive severe hypoglycemia, organ and tissue overgrowth, joint and nerve pain, fluid retention, and concerns about accelerating the growth of existing tumors, with no medical oversight or quality control over unregulated vials. Dosing errors, contamination, and interactions with insulin or anabolic steroids make the danger unpredictable from person to person, and several factors influence how serious symptoms become. See below to understand more, including the warning signs that need urgent attention.
If you have used IGF-1 LR3 or are experiencing symptoms like shakiness, confusion, swelling, numbness, tingling hands, or unusual growth changes, it helps to get clarity fast instead of guessing, since low blood sugar and hormone-related complications can escalate within hours. A free, instant, online symptom check can help you organize what you are feeling, surface possible causes, and understand whether your next step is self-monitoring, a doctor visit, or emergency care.
Last reviewed for medical accuracy: 09/26/2026
IGF-1 LR3 (insulin-like growth factor-1 long arginine 3) is a synthetic version of a naturally occurring hormone, IGF-1. In your body, IGF-1 helps regulate growth, cell repair and metabolism. Scientists created IGF-1 LR3 by modifying the original IGF-1 molecule:
These changes slow down the rate at which the body breaks it down, giving it a much longer half-life (up to 20–30 hours vs. three hours for natural IGF-1). Because of that, IGF-1 LR3 remains active in your bloodstream longer and can provide a stronger, more sustained effect.
IGF-1 LR3 binds to the IGF-1 receptor on cell surfaces. Once activated, this receptor signals cells to:
In research settings and among some athletes or bodybuilders, IGF-1 LR3 is taken to boost muscle mass, speed up recovery, and improve overall body composition. However, its use outside of approved medical research is not well-regulated, and that’s where many of the risks come in.
While IGF-1 LR3 is not approved by health authorities for general medical treatment, proposed benefits include:
These potential outcomes have led to off-label and underground use, especially in sports and bodybuilding communities.
Even though it sounds appealing, IGF-1 LR3 carries several health risks. Many of these stem from its potent, long-lasting activity and the fact that it’s often manufactured and used without proper medical oversight.
IGF-1 LR3 mimics insulin-like actions, which can dramatically lower blood sugar levels.
IGF-1 LR3 promotes cell proliferation. While that’s useful for healing, it can also:
Prolonged exposure to high IGF-1 activity can cause:
Some users report:
Repeated injections in the same spot can lead to:
IGF-1 LR3 is often purchased through unregulated sources:
Altering levels of one growth factor can disrupt your entire endocrine system:
If you experience persistent or severe symptoms, it’s important to get medical advice right away.
If you’re considering IGF-1 LR3 for any reason, keep these points in mind:
Consult a Qualified Doctor
Always discuss with a physician before starting any hormone or peptide therapy. They can evaluate your health history and monitor your progress.
Verify Product Source
If you’re in a legitimate research setting, make sure your IGF-1 LR3 comes from a certified laboratory with batch testing and quality certificates.
Start with Low Doses
Medical studies often test very low doses to assess safety. Do not self-administer high doses based on anecdotal reports.
Monitor Blood Sugar
Regularly check fasting and post-meal glucose levels to catch hypoglycemia early.
Rotate Injection Sites
Prevent lipohypertrophy and skin issues by varying where you inject.
Track Side Effects
Keep a journal of any new symptoms (e.g., joint pain, swelling, headaches) and share them with your healthcare provider.
Lifestyle Support
Maintain a balanced diet, stay hydrated, and follow an appropriate exercise regimen. Peptide therapies are not a substitute for healthy habits.
Even with precautions, unexpected reactions can occur. If you notice any of the following, take action right away:
You might also consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to get initial guidance on what your symptoms could mean.
If you have anything that could be life threatening or serious, please speak to a doctor immediately.
IGF-1 LR3 is a powerful synthetic analog of a naturally occurring growth factor. While it offers theoretical benefits in muscle growth, recovery and tissue repair, it also carries significant risks:
Because of these risks—and the lack of regulatory oversight—anyone considering igf1 lr3 should proceed with extreme caution. Always involve a qualified healthcare professional to guide dosing, monitor side effects and safeguard your overall health.
Remember, no supplement or peptide can replace a balanced diet, consistent exercise and professional medical advice. If you have questions or start feeling unwell, speak to a doctor.
(References)
* Cao Y, Nimptsch K, Shui IM, Platz EA, Wu K, Pollak MN, Kenfield SA, Stampfer MJ, Giovannucci EL. Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. Int J Cancer. 2015 May 15;136(10):2418-26. doi: 10.1002/ijc.29295. Epub 2014 Nov 10. PMID: 25348852; PMCID: PMC4360136.
* Olszanecka A, Dragan A, Kawecka-Jaszcz K, Fedak D, Czarnecka D. Relationships of insulin-like growth factor-1, its binding proteins, and cardiometabolic risk in hypertensive perimenopausal women. Metabolism. 2017 Apr;69:96-106. doi: 10.1016/j.metabol.2017.01.005. Epub 2017 Jan 12. PMID: 28285656.
* Doria PLS, Moscovitz T, Tcherniakovsky M, Fernandes CE, Pompei LM, Wajman M, Nimwegen AV, Haimovich S. Association of IGF-1 CA(n) and IGFBP3 rs2854746 Polymorphisms with Endometrial Polyp Risk. Biomed Res Int. 2018;2018:8704346. doi: 10.1155/2018/8704346. Epub 2018 Dec 13. PMID: 30643822; PMCID: PMC6311315.
* Adachi Y, Nojima M, Mori M, Kubo T, Yamano HO, Lin Y, Wakai K, Tamakoshi A, for JACC Study. Circulating insulin-like growth factor binding protein-3 and risk of gastrointestinal malignant tumors. J Gastroenterol Hepatol. 2019 Dec;34(12):2104-2111. doi: 10.1111/jgh.14753. Epub 2019 Jul 24. PMID: 31158304.
* Larsson SC, Carter P, Vithayathil M, Kar S, Mason AM, Burgess S. Insulin-like growth factor-1 and site-specific cancers: A Mendelian randomization study. Cancer Med. 2020 Sep;9(18):6836-6842. doi: 10.1002/cam4.3345. Epub 2020 Jul 27. PMID: 32717139; PMCID: PMC7520358.
* Ebbesen M, Enevold C, Juul A, Heilmann C, Sengeløv H, Müller K. Insulin-Like Growth Factor Gene Polymorphisms Predict Clinical Course in Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol. 2020;11:1646. doi: 10.3389/fimmu.2020.01646. Epub 2020 Jul 24. PMID: 32793242; PMCID: PMC7393983.
* Bang P, Woelfle J, Perrot V, Sert C, Polak M. Effectiveness and safety of rhIGF1 therapy in patients with or without Laron syndrome. Eur J Endocrinol. 2021 Feb;184(2):267-276. doi: 10.1530/EJE-20-0325. PMID: 33434161; PMCID: PMC7849377.
* Xie Y, Huang C, Zhu X, Wang J, Fan X, Fu Z, Ma Y, Hang D. Association between circulating insulin-like growth factor 1 and risk of all-cause and cause-specific mortality. Eur J Endocrinol. 2021 Oct 11;185(5):681-689. doi: 10.1530/EJE-21-0573. Epub 2021 Oct 11. PMID: 34478404.
* Orenduff MC, Pieper CF, Allott EH, Coleman MF, Jung SY, Vitolins MZ, Fenton JI, Chen C, Kroenke CH, Tabung FK, Barac A, Paskett ED, Pollak MN, Hays-Grudo J, Chang S, Hursting SD. Plasma Insulin-like Growth Factor-Binding Protein-7 Is Positively Associated with Age, Obesity, Mortality, and Cancer in Postmenopausal Women. Cancer Epidemiol Biomarkers Prev. 2025 Jun 3;34(6):922-932. doi: 10.1158/1055-9965.EPI-24-1644. PMID: 40152978; PMCID: PMC12724625.
* Chen S, Liu M, Tan H, Ji L, Yu Y, Jiang S, Cai B, Wang W, Zheng S, Zan X, Xu H, Li J, Li J. Association between vertebral fracture risk and bone mineral density in patients with acromegaly. Pituitary. 2025 Dec 9;29(1):12. doi: 10.1007/s11102-025-01615-z. Epub 2025 Dec 9. PMID: 41364282.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.